Eliminating need to dilate

Article

Faster technology to be able to screen for diabetic retinopathy is a requirement as the disease is becoming more prevalent.

Faster technology to be able to screen for diabetic retinopathy is a requirement as the disease is becoming more prevalent. A new retinal imaging system has been confirmed to match or outperform fundus cameras in a recent clinical trial.

The DRIVE trial looked at 100 people with diabetes and examined the efficacy of the EasyScan (i-Optics). The performance of the system was assessed head-to-head with a fundus camera in the early diagnosis of diabetic retinopathy.

It was shown that the non-mydriatic confocal SLO technology successfully scanned all 100 patients without pharmacological dilation. Additionally, a large portion of the study group could be imaged in under 3 minutes. The results of this trial will be featured in ARVO and will add to the results of an earlier trial of the system’s imaging performance.

One of the first doctors to use the system in the US Dr Steven Squillace gave his opinion on the system. "I've worked with SLO technology for retinal evaluation over 10 years ago as part of a group practice. We saw the benefit of undilated fundus images, but also the drawback… When I heard there was a smaller version being launched, I thought it could be what I needed."

Dr Squillace has used the technology on over 100 patients and now states that he uses it exclusively for routine check ups.

If you would like to read more about the EasyScan the full article can be found in the May print issue of OTEurope.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.